Despite the logical concern that blocking the glucocorticoid receptor could cause adrenal insufficiency, the phase 3 ROSELLA study specifically monitored for this and reported zero cases. This key safety finding alleviates a major theoretical risk and should provide confidence for clinicians considering the drug.
Subgroup analysis of the ROSELLA trial shows a consistent overall survival benefit for the relacorilant-nab-paclitaxel combination, even in patients with a short interval (<6 months) since their last taxane exposure. This crucial finding supports using the regimen as a taxane re-challenge without concern for diminished efficacy.
While high glucocorticoid receptor (GR) expression is linked to chemoresistance and worse outcomes in ovarian cancer, clinical data found no correlation between GR levels and patient benefit from the GR antagonist relacorilant. This finding means no predictive biomarker test is required to select patients for this therapy.
The initial choice of nab-paclitaxel was to avoid corticosteroids typically given with paclitaxel, which would contradict relacorilant's mechanism. However, current practice often omits steroids with weekly paclitaxel, suggesting the combination might be feasible, broadening its potential application.
Recent trials for platinum-resistant ovarian cancer, including ROSELLA (relacorilant), show a pattern of small (e.g., one month) progression-free survival gains but much larger (e.g., four months) overall survival benefits. This suggests these therapies may positively influence the long-term disease course or response to subsequent treatments.
The historical six-month platinum-free interval is no longer a reliable measure in modern practice due to maintenance therapies and frequent imaging. Oncologists now favor a more nuanced, continuum-based approach using clinical judgment and quality of prior response to decide on re-treatment, rather than a rigid cutoff.
With multiple new effective options in platinum-resistant disease (relacorilant, pembrolizumab, ADCs), the key clinical question is shifting from choosing one superior drug to determining the optimal sequence. Biomarkers can guide initial choices, but sequencing multiple regimens, including re-using weekly paclitaxel backbones, is now a viable strategy.